Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Free Research Reports on BGMD, MCP, RSH and THLD Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit


Print article Print article
© Marketwire 2013
2013-01-28 14:50:42 -

NEW YORK, NY -- (Marketwire) -- 01/28/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.



BG Medicine, Inc. (NASDAQ: BGMD) shares plunged 15 percent on nearly 3 million shares traded Friday. The company earlier this month announced it has obtained a CE Mark for its first automated version of the BGM Galectin-3 blood test.



Find out more about BG Medicine including full access to the free equity report at: www.BedfordReport.com/BGMD : www.bedfordreport.com/BGMD





Molycorp Inc. (NYSE: MCP) shares of the rare earth miner rallied 13 percent on over 51 million shares traded Friday, which was nearly five-times the average daily volume. The company anticipates lower than expected revenue and cash flow for 2013. Molycorp is scheduled to release its fourth quarter results on February 18th.



Find out more about Molycorp including full access to the free equity report at: www.BedfordReport.com/MCP : www.bedfordreport.com/MCP



RadioShack Corporation (NYSE: RSH) surged 14.3 percent on over 5.5 million shares traded Friday. Last week, Zacks upgraded the company's rating to "neutral" from "underperform." Shares of RadioShack have plunged nearly 75 percent in the past year.



Find out more about RadioShack including full access to the free equity report at: www.BedfordReport.com/RSH : www.bedfordreport.com/RSH



Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) is focused on the discovery and development of drugs targeting tumor hypoxia. Threshold's partner, Merck KGaA, recently initiated a global Phase 3 MAESTRO study of TH-302, triggering a $30 million milestone payment.



Find out more about Threshold Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/THLD : www.bedfordreport.com/THLD



Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.



A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.




Contact Information:

Equity News Circuit
Email Contact : www2.marketwire.com/mw/emailprcntct?id=0B162999DB4EA810



Press Information:




Contact Person:


Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser